Streptococcus Agalactiae Clinical Trial
Official title:
A Double-blind, Randomized, Controlled, Parallel Groups Study for the Evaluation of the Effects of the Consumption of Lactobacillus BSL_PS71 on the Load of Streptococcus Agalactiae on Vaginal Mucosa.
The objective of this study is to evaluate the effects of oral administration of Lactobacillus BSL_PS71 on the presence of S. agalactiae in vaginal microbiota of healthy women.
Group B streptococci (Streptococcus agalactiae) are found in the vaginal microbiota in 10-30%
of women without showing signs of infection. However, during delivery, it can be transmitted
to the baby and, although in most cases it does not lead to disease, in a percentage of 5% of
babies it causes serious infections that can trigger the death of the baby. In order to avoid
this risk, a protocol of intra-partum preventive administration of antibiotics was implanted
decades ago in women with a positive vaginal culture for this species in the weeks before
birth. Taking into account the high percentage of women who show positive culture, this
represents a high percentage of women who receive preventive antibiotic treatment with the
consequences that this has for the mother's and baby's microbiota, as well as contributing to
the generation of antibiotic resistance, a serious problem for today's society.
The fecal microbiota is considered a source of bacteria for the vaginal microbiota. In fact,
women who present S. agalactiae in the vaginal microbiota also have it in stool. Given the
demonstrated ability of Lactobacillus to control certain bacterial populations, the ability
of a battery of Lactobacillus strains to inhibit the growth of S. agalactiae in the context
of the fecal microbiota was analyzed. From these tests the strain Lactobacillus BSL_PS71 was
selected for its antibacterial capacity against S. agalactiae.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00920530 -
Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study
|
N/A | |
| Completed |
NCT05005169 -
CCA of SGB PCR Versus SGB Culture at 35-38 SA in the Optimization of Intrapartum Antibiotic Prophylaxis
|
N/A | |
| Completed |
NCT02690181 -
Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
|
Phase 2 | |
| Completed |
NCT02046148 -
Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
|
Phase 2 | |
| Completed |
NCT01888471 -
Feasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])
|
N/A |